UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 10, 2009
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
TRANSACTION IN OWN SHARES
NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME
As part of the execution of Novo Nordisk A /S' overall DKK 19.0 billion share
repurchase programme for 2006-2009, a share repurchase programme has been
initiated in accordance with the provisions of the European Commission's
regulation no 2273/2003 of 22 December 2003, also referred to as the Safe
Harbour rules.
For that purpose Novo Nordisk A/S has appointed J. P. Morgan Securities Ltd. as
lead manager to independently and without influence from Novo Nordisk execute
the programme. The purpose of the programme is reduction of the company's share
capital. Under the agreement, J. P. Morgan Securities Ltd. will repurchase
shares on behalf of Novo Nordisk A/S for an amount of up to DKK 2.4 billion
during the trading period starting 10 August 2009 and ending on 18 December
2009. A maximum of 151,599 shares can be bought during one single trading day,
equal to 15% of the average daily trading volume of Novo Nordisk B shares on
NASDAQ OMX Copenhagen during the month of July 2009, and a maximum of 14,401,905
shares in total can be bought during the trading period. At least once every
seven trading days, Novo Nordisk will issue an announcement in respect of the
transactions made under the repurchase programme.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81
countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.
Further information:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
------------------- --------------------
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
krop@novonordisk.com
--------------------
In North America: In North America:
Sean Clements Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com hrmm@novonordisk.com
-------------------- --------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: August 10, 2009 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer